FGF21 and fatty liver disease: In addition, the fibroblast activation protein (FAP) inhibitor BR103354 blocks FGF-21 degradation, significantly prolonging half-life of FGF-21 and improving metabolic phenotypes and hepatic steatosis in diabetic mice [292].